Systemic Sclerosis Market Report- Global Drug Forecast and Market Analysis

The Systemic Sclerosis Market research report offers data regarding new recent developments, import/export analysis, value chain optimization, and trade regulations. In addition, Systemic Sclerosis Market data like market size, strategic market share, localized market players, analyses of opportunities in the emerging revenue pockets, strategic market growth, product launches, geographical expansions, and technological innovations are also encompassed in Systemic Sclerosis Market report.

Get FREE PDF Sample of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4547367

Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease that causes progressive fibrosis of the skin and internal organs, as well as vascular dysfunction. The presentation of the disease is heterogeneous, both in the organ systems affected and the overall severity of symptoms. The most common complications of SSc include digital vasculopathy (Raynaud’s phenomenon and digital ulcers), skin fibrosis, lung fibrosis or interstitial lung disease (ILD), pulmonary arterial hypertension, gastrointestinal issues, arthritis, myopathy, and scleroderma renal crisis. As there are no systemic disease-modifying therapies currently available that significantly alter the course of the disease, the SSc treatment paradigm is to manage complications within individual organ systems as they occur.

RNR report and forecast model focus specifically on the treatment of SSC-associated digital vasculopathy, skin fibrosis, and ILD. Most of the drugs used to treat these disease manifestations are decades-old generic agents that have been repurposed from other indications, including immunosuppressive agents (such as methotrexate, mycophenolate mofetil, and cyclophosphamide) and vasodilative cardiovascular drugs (such as calcium channel blockers, PDE5 inhibitors, and prostacyclin analogs). The vast majority of SSc therapies are used off-label. However, there has recently been a major shift in the SSc market landscape, and new players are beginning to enter the space.

RNR projects that the global SSc market, which comprises the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), will experience strong growth during the forecast period, at a Compound Annual Growth Rate (CAGR) of 14.0%, with sales growing from $498.0M in 2020 to $1.8B in 2030. Global growth in the SSc market will be driven by uptake of Boehringer Ingelheim’s (BI) recently launched Ofev (nintedanib) and Roche/Genentech’s Actemra/RoActemra (tocilizumab) for the treatment of SSc-associated ILD, along with the anticipated approval and launch of six pipeline therapies. This growth will be limited by sales erosion from generic nintedanib and biosimilars.

In Systemic Sclerosis Market report, RNR focuses its market forecast analysis on six Phase III and late Phase II products expected to be licensed for SSc between 2020 and 2030. These include four small molecule drugs Civi BioPharma/Eicos Sciences IV Civi-030 (iloprost), Horizon Therapeutics HZN-825, Kadmon Corporations belumosudil mesylate, and Mitsubishi Tanabe Pharmas dersimelagon and two monoclonal antibodies currently marketed for the treatment of PSO and PsAKyowa Kirins Lumicef (brodalumab) and J&Js Tremfya (guselkumab).

Although key opinion leaders (KOLs) interviewed by RNR were pleased to see such an innovative late-stage pipeline for SSc, they did highlight major, lingering unmet needs in the field. These include needs for the development of disease-modifying and anti-fibrotic therapies, earlier diagnosis and treatment, and improved prognostic biomarkers. KOLs were optimistic about the future of SSc but believed there was significant work left to be done in this space.

Key Highlights-
- The greatest drivers of growth in the global SSc market will be the recent launches of Ofev and Actemra/RoActemra for the treatment of ILD associated with SSc, the anticipated approval and launch of six pipeline therapies, a steadily climbing diagnosed prevalence rate, and a growing overall treatment rate due to growing access to new therapies.
- The main barriers to growth in the SSc market will be significant market share erosion from biosimilars and nintedanib generics as well as a historical treatment paradigm that focuses on the off-label use of inexpensive generic products.
- KOLs expressed enthusiasm for the six pipeline agents in development. Of these agents, KOLs were most interested in Civi Biopharma/Eicos Sciences’ Civi-030, Horizon Therapeutics’ HZN-825, and Kadmon Corporation’s belumosudil mesylate.
- The most important unmet needs in SSc are those for the development of disease-modifying and anti-fibrotic therapies, earlier diagnosis and treatment, and improved prognostic biomarkers.

KEY QUESTIONS ANSWERED-
For the first time ever, treatment options for patients with SSc are beginning to expand.
- What impact will the recently launched drugs, Ofev and Actemra/RoActemra, have on the treatment of SSc throughout the 7MM?
- What pipeline agents are currently in late-stage clinical development, and which are the most promising?

Growing interest in SSc by the pharmaceutical industry is transforming research and development practices in the field.
- What are the main R&D trends in the SSc market and which companies are leading the way?
- How is clinical trial design for SSc changing and in what ways does it differ depending on disease manifestation?

KOLs interviewed by GlobalData have indicated that there are still many remaining unmet needs within the SSc indication.
- What are the main unmet needs in the SSc market?
- How can the pharmaceutical industry address these needs?
- To what degree will the therapies under development fulfill these unmet needs?

Scope of this Report-
- Overview of SSc including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline SSc therapeutics market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting SSc therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global SSc therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy this Report-
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global SSc therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SSc market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global SSc therapeutics market from 2020-2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Discount on Purchase this Report @ https://www.reportsnreports.com/purchase.aspx?name=4547367

List of Tables in this Report-
Table 1: SSc Key Metrics in the 7MM
Table 2: Classification Groups for SSc
Table 3: Risk Factors and Comorbidities for SSc
Table 4: Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement
Table 5: 2013 ACR/EULAR Criteria for the Classification of SSc
Table 6: Frequency and Clinical Correlation of Select SSc-associated Nuclear Autoantibodies
Table 7: Treatment Guidelines for SSc
Table 8: Comparison of Provisional ACR-CRISS and Revised ACR-CRISS
Table 9: Key Deals in SSc Market, 2016-2021
Table 10: SSc Market - Global Drivers and Barriers, 2020-2030
Table 11: Key Events Impacting Sales for SSc in the US, 2020-2030
Table 12: SSc Market - Drivers and Barriers in the US, 2020-2030
Table 13: Key Events Impacting Sales for SSc in the 5EU, 2020-2030
Table 14: SSc Market - Drivers and Barriers in the 5EU, 2020-2030
Table 15: Key Events Impacting Sales for SSc in Japan, 2020-2030
Table 16: SSc Market - Drivers and Barriers in Japan, 2020-2030
Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

+ 1 888 391 5441
sales@reportsandreports.com

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

This release was published on openPR.